Repaglinide
- Generic Name
- Repaglinide
- Brand Names
- Enyglid, Gluconorm, Prandin, NovoNorm, Repaglinide Krka, Repaglinide Accord, Repaglinide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O4
- CAS Number
- 135062-02-1
- Unique Ingredient Identifier
- 668Z8C33LU
- Background
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood ...
- Indication
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 213
- Registration Number
- NCT01562561
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Tainan city, Taiwan
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 27
- Registration Number
- NCT01536366
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Observational Study of NovoNorm® in Subjects With Diabetes
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5841
- Registration Number
- NCT01498913
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30554
- Registration Number
- NCT01498900
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 93
- Registration Number
- NCT01490658
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Austin, Texas, United States
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT01489644
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 182
- Registration Number
- NCT01465152
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 120
- Registration Number
- NCT01355718
An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2033
- Registration Number
- NCT01077570
Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 440
- Registration Number
- NCT01022762
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.